Re: The new competitors: SGLT2 inhibitors and GLP-1 Receptor Agonists

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: The new competitors: SGLT2 inhibitors and GLP-1 Receptor Agonists

in response to

The new competitors: SGLT2 inhibitors and GLP-1 Receptor Agonists

BearDownAZ

posted on Jun 14, 2016 11:25AM

Also noteworthy is that Liraglutide reduced "nephropathy events" by 22% (p=0.003) in LEADER and Empagliflozin reduced "incident or worsening nephropathy" by 39% (p<0.001) in EMPA-REG OUTCOME renal sub-analysis. A prespecified secondary objective of EMPA-REG OUTCOME was to examine the effects of empagliflozin on microvascular outcomes and, in particular, progression of kidney disease in patients with type 2 diabetes at high risk for cardiovascular events. This study, just announced today at American Diabetes Association and published today in NEJM, provides good reason for Resverlogix to go after kidney disease in their upcoming kidney trial(s).